



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi-110019(INDIA)

Tel.: 011 -47589500-51 (50
Lines)
Email.: info@medicamen.com
Web : www.medicamen.com
CIN
No.:L74899DL1993PLC056594

Ref: STEX/Results/Published-2020-21

Date: 02.07.2020

The BSE Ltd
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

**Sub. : Copy of Publication of Notice for Audited Financial Results for the Quarter and year ended 31st
March, 2020**

Dear Sir,

The Board of Directors at their Meeting held on 30.6.2020 adopted the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2020.

The copy of the results published in the Financial Express and Jansatta dated July 1, 2020 is enclosed.

This is for your information and records.

Thanking You,

Yours truly,

For Medicamen Biotech Limited

Sd/-
Parul Choudhary
Company Secretary

Encl: As above.

with the Stock Exchanges (Regulations, 2015. The of the Company i.e. (com). Board at their meeting

g Standards (Ind-AS) as (As amended). the Board of Directors of Quasar India Limited Sd/- Harish Kumar (Director) DIN: 02591868

New Delhi-110085 shreeworstex.in, 113790

(₹ in lacs)

to date	Corresponding 3 months ended in the previous year
3.2020	31.03.2019 (Audited)
37.90	0.34
(0.45)	(22.21)
(0.45)	(22.21)
(0.45)	(16.49)
35.82	2.13
314	314
60.08	69.38
(0.01)	(0.53)
(0.01)	(0.53)

ch 31, 2019 have been of the Company at their ial Results along with want to the Regulation ations, 2015 received

Results filed with the closure Requirements) s are available on the mitted (www.msel.in), shreeworstex.in).

the Board of Directors hree Worstex Limited Sd/- Pawan Kumar Mittal Director DIN: 00749265

D.

780400

	End of previous year					
8 Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)						
Basic:	2.08	4.89	6.35	7.74	10.16	11.82
Diluted:	2.08	4.89	6.35	7.74	10.16	11.82

Note:

- The Audited Financial Statement for the year ended March 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30th June, 2020
- The figures are regrouped in previous year also, wherever considered necessary
- The Company operates only in on business segment, viz Agro Chemical, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Ind AS-33.

For Shivalik Rasayan Limited Sd/- Rahul Bishnoi Chairman

Place: New Delhi Date : 30.06.2020



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019 (CIN: L74899DL1993PLC056594) Website: www.medicamen.com Email id: cs@medicamen.com

Extracts of Audited standalone Financial Results for the Quarter and Year ended on 31.03.2020

(In Lakhs)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2020	Audited 31.03.2019	Audited 31.03.2020	Audited 31.03.2019	Audited 31.03.2020	Audited 31.03.2019
1	Total income from operations (net)	1642.97	2415.37	11925.09	12626.32	12744.26	12626.32
2	Net Profit/ (Loss) for the period (before tax, exceptional and/or Extraordinary items)	200.86	365.59	1660.39	1752.28	1798.02	1752.28
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	200.86	365.59	1660.39	1752.28	1798.02	1752.28
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	146.11	240.45	1225.89	1202.58	1329.12	1202.58
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	1221.66	1170.00	1221.66	1170.00	1221.66	1170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)						
	Basic:	1.20	2.06	10.09	10.28	10.94	10.28
	Diluted:	1.20	2.06	10.09	10.28	10.94	10.28

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 30th June 2020.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per IND AS-33.
- Auditor's Report has been carried out by the Statutory Auditors for the above period.
- During the quarter-4, the order for Paracetamol, metronidazole, Azithromycin worth Rs 18 crore were cancelled due to the ban imposed by Govt. of India for Covid-19.
- Medicamen Biotech Limited has acquired controlling stake in Opal Pharmaceuticals Pty, Australia during the year. Opal Pharmaceuticals Pty, Australia, figures have been consolidated at the end of the year.

For Medicamen Biotech Limited Sd/- Rahul Bishnoi Chairman

Place: New Delhi Date : 30.06.2020

ADVERTISEMENT OF NOTICE TO EQUITY SHAREHOLDERS OF HUGHES COMMUNICATIONS INDIA PRIVATE LIMITED

Notice is hereby given that by the order of the Hon'ble Company Law Tribunal at New Delhi (CA(CAA)-186(PB) of 2019) the meetings to be held of the equity shareholders of Hughes Communications India Limited ("HCIL") and unsecured creditors of HCIL ("HCIL Comtel") which the purpose of considering and proposed composite scheme of arrangement between Hughes Communications India Limited and unsecured creditors of HCIL Comtel under Sections 230 to 232(3) of the Companies Act, 2013 ("Act").

In pursuance of the Order and a meeting of the equity shareholders of HCIL Comtel on August, 2020 between 10:30 A.M. to 12:00 P.M. by audio visual means ("VC/OAVM") of HCIL Comtel are requested to attend the meeting.

(ii) Meeting of the unsecured creditors of HCIL Comtel on August, 2020 between 12:00 P.M. to 2:00 P.M. by audio visual means ("VC/OAVM") of HCIL Comtel are requested to attend the meeting.

(iii) Meeting of the equity shareholders of HCIL Comtel on August, 2020 between 2:00 P.M. to 4:00 P.M. by audio visual means ("VC/OAVM") of HCIL Comtel are requested to attend the meeting.

(iv) Meeting of the unsecured creditors of HCIL Comtel on August, 2020 between 4:00 P.M. to 6:00 P.M. by audio visual means ("VC/OAVM") of HCIL Comtel are requested to attend the meeting.

Please note that there shall be a meeting of the equity shareholders of the Companies (as applicable) are through VC/OAVM at the above meetings shall however be deemed to be a meeting of the Companies (as applicable) which the purpose of considering and proposed composite scheme of arrangement between Hughes Communications India Limited and unsecured creditors of HCIL Comtel under Sections 230 to 232(3) of the Companies Act, 2013 ("Act").

Persons entitled to attend and vote at the meeting shall be those whose names are made available during the meeting. Proxies will not be available for appointment a representative for the meeting.

Notice under Section 230(3) of the Companies Act, 2013. The relevant Explanatory Statement to the notice (together, the "Notice") is available on the website of the Companies (as applicable). Further details are available on the website of HCIL Comtel (as applicable). Further details are available on the website of HCIL Comtel (as applicable).

Important: Notices are not to be presented in person. Notices should be sent to the registered office of the Companies (as applicable) at the address mentioned in the notice.

Copies of the Notices in relation to the proposed scheme of arrangement are available on the website of the Companies (as applicable) under Sections 230(3), 232(1), 232(2) of the Companies Act, 2013. The notices are available free of charge on any of the registered offices of the Companies (as applicable) at the address mentioned in the notice.

The unsecured creditors of the Companies (as applicable) are requested to send their names to the representatives of the Companies (as applicable) at the address mentioned in the notice. The Tribunal has appointed Mr. and failing him, Mr. Saurabh Singh as the scrutineer for the meeting. The Tribunal has a Secretary, as the scrutineer for the meeting, if approved at the meeting of the Tribunal.

The results of the votes cast at the meeting shall be announced on Monday, August 3, 2020. The results of the votes cast at the meeting shall be displayed at the registered office of the Companies (as applicable) at the address mentioned in the notice.

The results of the votes cast at the meeting shall be announced on Monday, August 3, 2020. The results of the votes cast at the meeting shall be displayed at the registered office of the Companies (as applicable) at the address mentioned in the notice.

Sd/- Mr. Pranav Roach (Director & Authorized Signatory) Hughes Communications India Private Limited (Formerly known as Hughes Communications India Limited) CIN - U64202DL1992PTC048053 Regd. Office: 01, Shivaji Marg, West Block, N.H.-8, New Delhi-110 037, India www.hughes.in

Dated this 1st day of July, 2020

HARYANA GOVERNMENT TENDER NOTICE

SR. No.	NAME OF BOARD/CORP./AUTH	NAME OF WORK NOTICE TENDER	OPENING DATE CLOSING DATE (TIME)	AMOUNT / EMD (APPROX.) IN RUPEES	WEBSITE OF THE CORP./AU
		REPLACING OF EXISTING ACC SHEET OF COVERED SHED ,CONST OF			

SECURITIES LIMITED
KUSHWAHA
DIRECTOR

mail.com,
का विवरण

(रु. हजारों में)

समाप्त वर्ष	अंकित	अंकित
31.03.2020	31.03.2019	
2357.40	480.00	
323.79	15.28	
323.79	15.28	
178.49	0.50	
8269.21	8269.21	
2660.84	2485.16	
0.22	0.00	
0.22	0.00	
0.22	0.00	
0.22	0.00	

में दाखिल की गई 31 मार्च, 2020
एकसय में दाखिल की गई है।
म 2015, समय-समय पर यथा
(इंड ए एस) के अनुसार तैयार

या 30 जून, 2020 को आयोजित
विवरण की कम्पनी के संचालक

के पुनर्समूहीकृत/पुनर्वगीकृत किये
बंधित टिप्पणी में "0" में दर्शाया

का विवरण

(रु. हजारों में)

समाप्त वर्ष	अंकित	अंकित
31.03.2020	31.03.2019	
20059.16	22646.91	
7714.64	16488.31	
7714.64	16488.31	
5588.03	11890.98	
8269.21	8269.21	
485899.95	480314.71	
6.76	14.38	
6.76	14.38	
6.76	14.38	
6.76	14.38	

में दाखिल की गई 31 मार्च, 2020
एकसय में दाखिल की गई है।
म 2015, समय-समय पर यथा
(इंड ए एस) के अनुसार तैयार

या 30 जून, 2020 को आयोजित
विवरण की कम्पनी के संचालक

के पुनर्समूहीकृत/पुनर्वगीकृत किये
बंधित टिप्पणी में "0" में दर्शाया

भारत एकांश लिमिटेड के लिये
हस्ता/-
मुकेश कुमार शर्मा
(सीएफओ)

29.06.2020 पढा जाए और जगह नई दिल्ली के बजाए
फरीदाबाद पढी जाए। अन्य नियम व शर्तें वही रहेंगी।
अधिकृत प्राधिकारी, एसएएमबी- I, नई दिल्ली

इंडिया फिनसेक लिमिटेड

पंजीकृत कार्यालय: डी-16, प्रथम फ्लोर, आईआईटीआई बैंक के
ऊपर, प्रसन्न विहार, सेक्टर-14, रोहिणी, दिल्ली-110085
CIN: L65923DL1994PLC060827,
फोन: 011-47994997

वेबसाइट: www.indiafinsec.com,
ई-मेल आईडी: indiafinsec@gmail.com

सूचना
सेबी (सूचीकृत दायित्व तथा उद्घाटन अपेक्षा) विनियमन 2015 के विनियमन
29 के साथ परित विनियमन 47 के अनुपालन में एनएचएल सूचित किया जाता
है कि मैं इंडिया फिनसेक लिमिटेड के निदेशक मंडल को बैठक पुनर्निर्धारित
की गई है जो सोमवार, 6 जुलाई, 2020 को कम्पनी के पंजीकृत कार्यालय में
आयोजित होगी जिसमें 31 मार्च, 2020 को समाप्त तिमाही एवं वित्त वर्ष के
अंतिम रिजल्ट्स तथा समेकित वित्तीय परिणाम तथा अल्पक की अनुमति से
किसी अन्य विषय पर विचार तथा अनुमोदन किये जाएंगे। विस्तृत विवरण
कम्पनी की वेबसाइट <http://www.indiafinsec.com> एवं स्टॉक
एक्सचेंज की वेबसाइट www.bseindia.com देखें।

इंडिया फिनसेक लिमिटेड के लिये
हस्ता/-
मोहम्मद बंसल
प्रबंध निदेशक

करो' का रुख अख्तियार किया।
प्रधानमंत्री ने बाजार बंद होने के बाद
अपने संबोधन में 80 करोड़ लोगों के
लिए मुफ्त राशन योजना, प्रधानमंत्री
गरीब कल्याण अन्न योजना

हुए। शुरुआती कारोबार में यूरोपीय
बाजारों में गिरावट का रुख था।
अंतरराष्ट्रीय बेंचमार्क ब्रेट कच्चा तेल
वायदा 1.36 फीसद टूटकर 41.28
डॉलर प्रति बैरल रह गया।

फिलिप्स ने भारत में पेश किया चलता-फिरता आइसीयू

नई दिल्ली, 30 जून (भाषा)।

स्वास्थ्य रक्षा से जुड़ी प्रौद्योगिकी पर
काम करने वाली वैश्विक कंपनी रॉयल
फिलिप्स ने देश में चलते-फिरते
आइसीयू (सघन चिकित्सा कक्ष) पेश

किए हैं। कंपनी ने मंगलवार को कहा कि
यह आइसीयू देश के दूरदराज के इलाकों
और जरूरत पड़ने पर सघन चिकित्सा
देखभाल की चुनौतियों से निपटने में
मदद करेगा।

फिलिप्स ने एक बयान में कहा कि
मरीजों की सघन
चिकित्सा जरूरतों को
पूरा करने में इन पहले से
तैयार आइसीयू की
क्षमता नौ बिस्तरों की है।
इनका विनिर्माण कंपनी
देश के भीतर ही कर रही
है। कंपनी ने कहा कि
इन आइसीयू को कहीं
भी एक दिन में असेंबल
किया जा सकता है।
कहीं भी लाने-ले जाने
में सक्षम ये आइसीयू
सरकारी एंजिनियों को
मौजूदा कोविड-19
संकट के साथ-साथ
प्राकृतिक आपदा के
समय में भी स्वास्थ्य
सेवाएं देने में मदद
करेंगे।

फिलिप्स इंडिया के
उपाध्यक्ष और प्रबंध
निदेशक डेनियल मेज़न
ने कहा कि कंपनी इन
आइसीयू को सीधे
अस्पतालों को बेचेगी।
सरकार के गुणवत्तापूर्ण
स्वास्थ्य सेवा तक
सबकी पहुंच उपलब्ध
कराने के दृष्टिकोण के
अनुरूप अपने ऐसे
अत्याधुनिक आइसीयू
को पेश करते हुए हमें
खुशी है। इसकी कीमत
के बारे में कंपनी ने
कहा कि नौ बिस्तर की
क्षमता वाले पहले से
तैयार आइसीयू की
कीमत लगभग एक
करोड़ रुपए से शुरू
होती है। इसकी क्षमता
को ग्राहक की जरूरत
के मुताबिक बदला भी
जा सकता है।



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

Extracts of Audited standalone Financial Results for the Quarter and Year ended on 31.03.2020
(In Lakhs)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2020	Audited 31.03.2019	Audited 31.03.2020	Audited 31.03.2019	Audited 31.03.2020	Audited 31.03.2019
1	Total income from operations (net)	1642.97	2415.37	11925.09	12626.32	12744.26	12626.32
2	Net Profit/ (Loss) for the period (before tax, exceptional and/or Extraordinary items)	200.86	365.59	1660.39	1752.28	1798.02	1752.28
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	200.86	365.59	1660.39	1752.28	1798.02	1752.28
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary Items)	146.11	240.45	1225.89	1202.58	1329.12	1202.58
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	1221.66	1170.00	1221.66	1170.00	1221.66	1170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)						
	Basic:	1.20	2.06	10.09	10.28	10.94	10.28
	Diluted:	1.20	2.06	10.09	10.28	10.94	10.28

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 30th June 2020.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per IND AS-33.
- Auditor's Report has been carried out by the Statutory Auditors for the above period.
- During the quarter-4, the order for Paracetamol, metronidazole, Azithromycin worth Rs 18 crore were cancelled due to the ban imposed by Govt. of India for Covid-19.
- Medicamen Biotech Limited has acquired controlling stake in Opal Pahraceuticals Pty, Australia during the year. Opal Pharmaceuticals Pty, Australia, figures have been consolidated at the end of the year.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 30.06.2020